76725
document
Domperidone , metoclopramide , and placebo . All give symptomatic improvement in gastroesophageal reflux . A double-blind crossover study was conducted of two gastric prokinetic drugs in 23 patients with gastroesophageal reflux . Patients were divided into two groups on the basis of a dual-isotope mixed-meal study of their gastric emptying ( GE ) . Group I had normal GE and group II delayed GE . Nine gastrointestinal symptoms were assessed for frequency and severity before treatment . The trial had three 1-month treatment periods using metoclopramide 10 mg q.i.d. , domperidone 20 mg q.i.d. , or placebo on a random basis . Symptoms were reassessed at the end of each month . Taken as a whole , the group showed a significant symptomatic response in all three treatment periods ( p less than 0.0001 ) , but patients with delayed or normal GE did not differ significantly in their symptomatic response . Eleven patients complained of side effects with metoclopramide and three stopped therapy before the 1-month course was completed . Two patients described side effects with domperidone , including one woman with galactorrhea after 36 h of treatment . Three patients on placebo also complained of important side effects . We conclude that a significant placebo effect is present in the treatment of gastroesophageal reflux . No significant difference was demonstrated in symptomatic improvement between placebo , domperidone , and metoclopramide in this study .
76726
Intervention_Pharmacological
gastric prokinetic drugs
76727
Intervention_Pharmacological
domperidone
76728
Intervention_Control
placebo
76729
Intervention_Pharmacological
metoclopramide
76730
Outcome_Physical
symptomatic response
76731
Outcome_Adverse-effects
side effects
76732
Outcome_Adverse-effects
galactorrhea
76733
Outcome_Adverse-effects
important side effects
76734
Outcome_Other
symptomatic improvement
76735
Participant_Sample-size
23 patients
76736
Participant_Condition
gastroesophageal reflux